Natick, MA, November 5, 2021. Genius Biotechnology, Inc., a cell therapy company focused on cancer, and inventor of SMAR-TTM cells, today announced that Salvatore M. Buscemi has joined its advisory board.
“We are very pleased that Sal has agreed to join Geneius’ advisory board,” said Alfred Slanetz, Ph.D., CEO. “Sal has been advising us on an informal basis now for some time and provided critical advice and contacts during our early growth phase. Now that we expect to move into the clinical development phase, it is time to formalize that relationship to secure his advisory services. Sal was one of the earliest investors and has successfully led a consortium of other sophisticated investors to the Company.,” said
Slanetz.
“I am quite pleased to become an advisor to Geneius alongside it’s other distinguished participants.,” said Buscemi. “I have followed along as its technology achieved milestone after milestone and as it has assembled a small group of superb, dedicated, and experienced professionals who have worked through all the disruptions caused by COVID and challenges under the constraints of early-stage financings to bring the technology forward.. “In the new post-pandemic world, it has been fascinating and inspiring to hear of Geneius’ new developments and their potential to make a major impact on the experiences and outcomes of cancer patients. I look forward to helping Geneius as it moves forward.” Buscemi continued. “For me, as a finance professional and allocator, it’s been especially impressive that senior executives are so inspired by the potential that they have taken no salary for several years to dedicate the earlier-
staged funding to technology development and that Dr. Slanetz, the CEO, has also invested $1.5 million of his own money. That is an alignment of interests you only see working with world-class entrepreneurs with confidence in their technology and established track records of success,” Buscemi concluded.
Geneius Biotechnology, Inc., located in Natick MA, is a pre-clinical biotechnology company. Its SMAR-TTM cells are designed to deliver effective therapy, with negligible toxicity that is unique for each person’s cancer, targeted only at mutations, and made by a reproducible process against at least 20 different mutations in a single production run, at a low cost of manufacturing. The Company expects to begin its first clinical trial 9-10 months after financing.
Salvatore M. Buscemi is the CEO and co-founder of Dandrew Partners, a private family investment office, and has managed money successfully for almost 20 years through the creation of multiple portfolios into various cross-asset platforms. This includes Dandrew Partners Encore Ventures, The Dandrew Partners Fine Art Enhanced Income Credit Fund, and various commercial real estate and special situation direct investment allocations. In 2008, Mr. Buscemi also has launched two separate successful distressed credit platforms backed by a $2 billion NYC-based asset manager and a $1 billion commercial real estate investment manager. Mr. Buscemi is the author of several books on investing. His most recent work, Legacy Investing: How The .001% Invest, reveals the concerns, passions, and prejudices of the world’s wealthiest families and how that influences their investment decision-making.
Mr. Buscemi is a frequent speaker and guest lecturer on real estate finance at professional symposia and has written numerous articles on the topic of real estate and private equity finance in various publications, including Investor’s Business Daily, Forbes, and on television shows such as CBS New York, and Good Morning LaLa Land. Mr. Buscemi started his career at Goldman Sachs in the Investment Banking Division and is a graduate of Fordham University in New York City.
Comentários